Patients who were diagnosed with ILD during the follow-up period and treated with FXa inhibitors had a higher risk of ILD requiring consequent antifibrotic agents than those who were treated with warfarin (odds ratio [OR], 3.01; 95% CI, 0.87-10.46; P = .03). This evidence concerns the gene F10 and interstitial lung disease.